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RESPONSE: SETTING THE STAGE FOR IMPROVEMENT AND 
ACCOUNTABILITY
Linda Bradshaw, M.A.; Deborah Garnick, Sc.D.; and Daniel R. Kivlahan, Ph.D. 
Deborah Garnick: Dr. McCorry provides
a concise overview of several large, national
efforts in performance measurement and
quality improvement. He has done an excel-
lent job of bringing together the work of the
Washington Circle, Network for the
Improvement of Addiction Treatment
(NIATx), National Outcome Measures, and
Clinical Trials Network. The article is a fine
starting point for someone to get a sense of
the landscape and to jump off, using the
links and references he provides, to more
detail about each of the projects.
Daniel Kivlahan: I particularly like the image
of the three-legged stool, emphasizing how
interrelated these three major themes are—
the content, the data and measurement fea-
tures, and then the quality improvement
efforts. That’s the broad context that makes
a huge difference in how far a particular agency
is likely to get with implementation.
Each of the projects discussed in the
paper provides a different spectrum of options
for instituting quality and performance 
measurement and improvement. The NIATx
system starts at the front door of the organ-
ization, so it can give a lot of clues about
patient-level experiences and barriers to bet-
ter outcomes that programs might overlook.
The National Registry of Evidence-Based
Programs and Practices becomes useful when
clients have gotten through those early treat-
ment hoops and are waiting for at least some
initial intervention.
Linda Bradshaw: Of Dr. McCorry’s tips
on how to get started, I was impressed by
the create-a-crisis concept: challenging your
local boards and people in your agency to
take a hard look at the wave of the very near
future and start getting ready for it. That
seems a very practical way to go about get-
ting someone’s attention.
Kivlahan: Another approach might be to
ask the line staff what kind of information
was on the last list or spreadsheet they saw.
For example, staff members frequently get
lists of chart deficiencies, things they haven’t
documented appropriately. Reviewing these
together would reinforce the commitment
to measurement by reiterating the impor-
tance of the items on the list. The discussion
might produce a consensus that you are track-
ing the right things, or it might lead to a shift
to other, more productive measures.
Selecting practices
Garnick: The National Quality Forum
report, Evidence-Based Practices to Treat
Substance Use Conditions,is currently avail-
able on the Web for public comment. I
think people will be pleasantly surprised to
see that it talks about general practices and
approaches, not specific applications. For
example, it calls for more efforts at screen-46 • SCIENCE & PRACTICE PERSPECTIVES—APRIL 2007
ing people for substance abuse or alcohol
problems, but does not specify whether you
should use instrument A, B, or C. The goal
is to give providers a sense of which
approaches have good evidence behind
them without binding them to a cookbook-
style approach.
Kivlahan: The Forum’s perspective on psy-
chosocial approaches, similarly, will be that
we don’t have compelling evidence that there
is one treatment of choice. I think providers
will appreciate this. When they are asked to
adopt evidence-based practices, providers
often want to know: What about this approach
is fundamentally different from what I was
already doing, and why is it going to work
better? The Forum’s perspective is: We can’t
yet clearly identify the precise elements of
our evidence-based practices that make them
effective; if we could, we might very well
find that many of our excellent clinicians
are already supplying those elements in the
care they give. Therefore, as long as what
clinicians are doing fits in with some 
evidence-based rationale, it makes no sense
to ask them to change to a different model
just because it appears on a list.
While evidence-based practices are indis-
pensable starting points for quality assur-
ance and improvement, they do not auto-
matically resolve all issues. One important
concern is that they don’t yet guide care over
the course of treatment. A lot of the tough
calls that are made over the course of care
aren’t guided by the kinds of things that
appear in the National Registry. They are
process-of-care decisions. This isn’t unique
to addiction; it is the case in other medical
areas as well.
As important as implementing proven
models is discontinuing approaches that
don’t work well. Kicking people out 
of programs for relapse is a good example,
where the consequences are negative and
pervade a whole clinical culture. Lists of 
evidence-based practices don’t specify what
should be de-implemented, but these deci-
sions are hugely important.
The choice of indicators
Kivlahan: Much rides on measuring the
right indicators. There are often unintended
consequences if you pick something inap-
propriate or don’t recognize how what you
choose is linked to other important pieces
of the service delivery system. In the VA, we
tried for years to get providers to do a 
systematic assessment with the Addiction
Severity Index at intake and then follow up
with patients 6 months later, whether the
patient was still in treatment or not. It was
a frustrating experience for everyone, because
most patients were long gone after 6 months.
Finally we switched to tracking the per-
centage of patients who are still actively
involved in treatment after 3 months. That
provides us with an adequate and much more
practical nationwide, benchmarked indica-
tion of how well programs are retaining
patients.
Retention is the best proxy for outcomes,
and the new indicator works great overall.
But even it works at cross purposes with
some goals. As we push to identify needs
and manage care outside of specialty set-
tings, we are finding that nonspecialty
providers may avoid offering care that will
trigger responsibility for tracking the indi-
cator.
Garnick: That’s why the Washington Circle
has worked hard to have the National
Committee for Quality Assurance adopt all
three of our measures, including patient iden-
tification, treatment initiation, and engage-
ment. We are concerned that if NCQA 
only looks at identification, health plans will
have an incentive to do all sorts of screening
and outreach, but will not follow through
with services for the people they identify.
Alternatively, if NCQA omits the initiation
measure, the plans will have no incentive to
reach out and try to find the people in their
health plans who need services. Instead, they
would be rewarded for making sure a small
number of clients stick with their treatment
for the initiation (14 days) and engagement
(another 30 days) periods.
Bradshaw: Several States—Oklahoma,
North Carolina, and Connecticut are exam-
ples—are taking a top-down approach.
They use data that programs already are
submitting in administrative filing to cre-
ate reports, based on the Washington Circle
and other measures, which they feed back
to providers. This is on a quarterly basis,
so turnaround is pretty fast. The idea is to
try to get providers across the State on
the same page with regard to a relatively
parsimonious set of items, looking at what
the rates are, how they vary, and how they
can be influenced.
To date, the States using this approach
have not been very successful in talking
with providers about how to interpret and
use the measures. Still, I see some promise
in the effort. For example, one of their meas-
ures is how many clients had follow-up serv-
ice within 14 days after being discharged
from relapse, and at first they found a very
low rate. This led to the revelation that their
stand-alone detox provider did not under-
stand that it was responsible for making
sure clients got to treatment afterward.
When the provider grasped that this was
something that mattered to the State, they
brought in a case manager.
Pay for performance
Bradshaw:Delaware’s pay-for-performance
system uses standards that are closely related
to those of the Washington Circle. They
specify the frequency of treatment at each
stage—I think twice a week for the first 4
weeks and a little less than that for the next
4 weeks. For the top level of funding, pro-
grams have to document that 90 percent
of clients reach those goals. Dr. Jack Kemp,
the State director of alcohol and drug serv-
ices, and Dr. Thomas McLellan, the admin-
istrator, feel they have had great success
with the program. They will tell you, though,
that they’ve been greatly helped by the small
size of the State, which has permitted a very
communicative, hands-on approach that
might be more difficult in more spread-out
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Kivlahan: One principle we can generalize
from Delaware’s approach is that standards
need to be achievable. Otherwise, providers
and managers feel like meeting them is just
another thing that would be good to do in
an ideal world.
Bradshaw: One of the tensions in the move
toward pay for performance in substance
abuse treatment is that not paying the under-
performing organizations puts them in a
place where they lack the resources to make
efforts toward quality improvement. It’s a
bit of a catch-22. There are ways to design
around the problem—for example, paying
programs on the basis of improvements they
make over their own baselines.
Kivlahan:  Agencies might be supported
based partly on the extent to which they are
willing to engage in the challenge of meas-
urement. Some agencies see measurement
as a big challenge that’s only going to set
them up for trouble, but, in my view, it is
essential. There has to be measurement,
there’s got to be feedback to people about
how they are doing on the measurement,
and then there has to be coaching to help
programs that fall short come up to the stan-
dard. If places refuse to engage in that process,
I don’t see how they can improve.  
The mother and the secretary
Bradshaw: Dr. McCorry’s hypothetical
mother’s situation points up the current lack
of guidance for patients and families who
need to choose a treatment program. The
mother’s best bet would be to call programs
and interview them. Honestly, though, I
think few people even know what questions
to ask to find out about a program’s per-
formance or how well it is likely to fit an
individual patient.
Garnick: For this purpose, we might want
to think about the analogy to the general
medical sector. Many States post hospital
report cards on the Web that are based on
generally accepted performance measures.
There are a lot of challenges to trying to
come up with accurate data and statistical
methods for these kinds of report cards.
There is a large literature on consumers’
ability to understand such information.
Nevertheless, it is being done, and mak-
ing substance abuse providers’ performance
data similarly available to the public may
be a logical next step once the measures now
under way are developed, tested, and imple-
mented. 
Kivlahan: I’m not yet convinced that per-
formance measures have immediate impli-
cations for choosing programs at the level
of the individual patient. I think they have
their greatest potential for helping programs
improve their own performance. A con-
sumer’s natural inclination is to try to find
out if other people have been satisfied with
that service. The evidence I’m familiar with
indicates that there isn’t a close relationship,
either in addiction treatment or in other
health care areas, between satisfaction and
outcome. 
Garnick:  That’s true, but some of the report
cards that are being put together for med-
ical provider groups are focusing on whether
or not patients in a practice receive the pre-
ventive services that they should have—that
kind of thing. If I were looking for a provider,
I’d look for one that was organized enough
to offer me the annual preventive services I
need. If I had a chronic condition like dia-
betes, I’d want them to be checking off
the six or eight things they should be doing
for me each year.
Kivlahan: I think it would be difficult to
get at anything equivalent to success rates
in heart surgery, with a chronic disease
like drug abuse. For patients in an acute state
or their family members, there are some
structural elements that might be consid-
ered. Does a program systematically mon-
itor abstinence, which will usually be with
urinalysis or breathalyzers? Do they have
the staffing depth necessary to address all
the patient’s co-morbid conditions? Do they
have somebody on the staff who is a capa-
ble prescriber, or do they have a close link-
age with resources that can do so?
Garnick: I hear us disagreeing about which
measures would be reasonable and useful to
families or potential clients, but agreeing
that there should be a systematic way for
people to access this kind of information.
Kivlahan: The assistant secretary Dr. McCorry
describes in his opening scenarios will have
to determine what counts for his State and
choose performance measures accordingly.
Do they want to spread minimal services
very broadly, which would mean maximiz-
ing the number of individuals seen by an
agency? Shouldn’t they also want to guar-
antee that all patients can receive at least 
a minimally sufficient dose of treatment,
which would require standards for reten-
tion and whatever other services promote
retention? These are difficult tradeoffs—
and more so in an environment of fund-
ing cuts.
Performance and quality measurements
don’t remove all of the hard decisions.
Programs, administrators, and clients still
have to decide what they value. &